Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Glaser

Orthopaedic Surgery Philadelphia, PA Medical Doctor

NPI 1972531432 CMS profile 180434

51 N 39Th Street, 1 Cupp Pavilion, Philadelphia, PA 19104

Open in the dashboard

General payments

$176,432

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Glaser of Philadelphia, PA is reported in the CMS Open Payments database as having received $176,432 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76,761 24
2024 General $56,806 28
2023 General $15,105 12
2022 General $23,415 4
2021 General $701 4
2020 General $482 4
2019 General $3,161 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Glaser
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to David Glaser were reported at $76,761. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year David Glaser Orthopaedic Surgery median Middle half National median
2019 $3,161 $644 $140–$2,844 $163
2020 $482 $312 $75–$1,860 $114
2021 $701 $520 $117–$2,495 $132
2022 $23,415 $598 $128–$2,731 $149
2023 $15,105 $461 $128–$2,264 $160
2024 $56,806 $497 $134–$2,475 $164
2025 $76,761 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medacta USA, Inc. $95,829 55 payments
  2. FX Shoulder USA, Inc $79,157 12 payments
  3. Encore Medical, LP $406 4 payments
  4. Catalyst OrthoScience $243 2 payments
  5. Integrity Orthopaedics, Inc. $145 1 payment
  6. Arthrex, Inc. $131 1 payment
  7. Exactech, Inc. $91 1 payment
  8. Acumed LLC $83 1 payment
  9. Smith+Nephew, Inc. $76 2 payments
  10. Orthofix Medical, Inc. $74 1 payment
  11. Other $197 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $73,312 2 payments
  2. Consulting Fee $69,425 9 payments
  3. Travel and Lodging $29,747 28 payments
  4. Food and Beverage $3,947 47 payments
Products named General payments · program years 2019–2025
  1. Shoulder System $36,801 25 payments
  2. Primary Shoulder Orthopedics/Orthopedic Surgery $26,041 17 payments
  3. Mecta-C Cervical Cages $19,850 1 payment
  4. PRIMARY SHOULDER Shoulder $12,911 9 payments
  5. DJO Surgical AltiVate Anatomic System $270 3 payments
  6. CSR & R1 Reverse Total Shoulder Systems $168 1 payment
  7. R1 Reverse Total Shoulder $168 1 payment
  8. Archer 3D Software $168 1 payment
  9. Integrity Orthopaedics $145 1 payment
  10. NextAR Shoulder $144 1 payment
  11. Other $1,180 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$233,708

Of which drugs: $5

Medicare patients

496

Average age 73

Services billed

1,057

275 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Ischemic heart disease 30%
Diabetes 21%
Depression 20%
Osteoporosis 20%
Chronic kidney disease 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 72 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record